(Q38255715)

1 September 2017

Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas? (English)

1 reference

1 September 2017

0 references

Jocelyn de Heer

1

1 reference

PubMed ID

25270593

1 September 2017

Burkhard Göke

series ordinal

2

1 reference

PubMed ID

25270593

1 September 2017

language of work or name

English

0 references

publication date

1 October 2014

1 reference

Expert Opinion on Drug Safety

1 September 2017

1 reference

1 September 2017

13

1 reference

1 September 2017

11

1 reference

1 September 2017

1469-1481

1 reference

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Is pancreatic diabetes (type 3c diabetes) underdiagnosed and misdiagnosed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Clinical practice. Acute pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Epidemiology, aetiology and outcome of acute and chronic pancreatitis: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

21 January 2018

The metabolic syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Gallstone disease: Epidemiology of gallbladder stone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Gallstone disease and related risk factors in a large cohort of diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Drug-induced acute pancreatitis: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Type 2 diabetes mellitus and the risk of acute pancreatitis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Acute pancreatitis due to diabetes: the role of hyperglycaemia and insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Inflammation, autophagy, and obesity: common features in the pathogenesis of pancreatitis and pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Paracrine and endocrine effects of adipose tissue on cancer development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Diabetes and cancer: a consensus report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Adipocytes as regulators of energy balance and glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Obesity and treatment of diabetes with glyburide may both be risk factors for acute pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Dose effect of thiazolidinedione on cancer risk in type 2 diabetes mellitus patients: a six-year population-based cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical t

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Antidiabetic therapies affect risk of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Studies in rodents with the dipeptidyl peptidase-4 inhibitor vildagliptin to evaluate possible drug-induced pancreatic histological changes that are predictive of pancreatitis and cancer development in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Pancreatic safety of GLP-1-based therapeutic agents: further insights from rodent studies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Hope and fear for new classes of type 2 diabetes drugs: is there preclinical evidence that incretin-based therapies alter pancreatic morphology?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Occurrence of spontaneous pancreatic lesions in normal and diabetic rats: a potential confounding factor in the nonclinical assessment of GLP-1-based therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

GLP-1-based therapies and the exocrine pancreas: more light, or just more heat?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Pancreatic safety of incretin-based drugs--FDA and EMA assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Informatic tools and approaches in postmarketing pharmacovigilance used by FDA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Reports of pancreatitis are 20-30 times more likely with GLP-1 drugs, analysis finds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Glucagon-like peptide 1-based therapies and risk of pancreatitis: a self-controlled case series analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Pancreas volumes in humans from birth to age one hundred taking into account sex, obesity, and presence of type-2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Beta-cell replication is increased in donor organs from young patients after prolonged life support

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Pancreatic volume is reduced in adult patients with recently diagnosed type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

The prevalence of pancreatic intraepithelial neoplasia in pancreata with uncommon types of primary neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

A cohort study of acute pancreatitis in relation to exenatide use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Risk of pancreatitis in patients treated with incretin-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Distant metastasis occurs late during the genetic evolution of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.955013

10.1517/14740338.2014.955013

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference

PubMed ID

25270593